Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants
Sponsor: Eisai Co., Ltd.
Summary
The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of tasurgratinib after a single dose administration.
Official title: An Open-label Parallel-Group Study to Evaluate Pharmacokinetics of E7090 and Its Metabolite in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
Key Details
Gender
All
Age Range
20 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2020-02-27
Completion Date
2026-11-30
Last Updated
2026-01-23
Healthy Volunteers
Yes
Conditions
Interventions
Tasurgratinib
Tasurgratinib oral tablet.
Tasurgratinib
Tasurgratinib oral capsule.
Locations (8)
Eisai Trial Site #6
Hakata, Fukuoka, Japan
Eisai Trial Site #4
Kurume, Fukuoka, Japan
Eisai Trial Site #2
Yuhu, Oita Prefecture, Japan
Eisai Trial Site #3
Bukyo-ku, Tokyo, Japan
Eisai Trial Site #1
Mintato-ku, Tokyo, Japan
Eisai Trial Site #8
Shinjuku-ku, Tokyo, Japan
Eisai Trial Site #5
Kofu, Yamanashi, Japan
Eisai Trial Site #7
Kyoto, Japan